Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

被引：0
|
作者：
E Elez
A Hendlisz
T Delaunoit
J Sastre
A Cervantes
R Varea
G Chao
J Wallin
J Tabernero
机构：
[1] Vall d’Hebron Institute of Oncology Barcelona,
[2] Spain and Universitat Autònoma de Barcelona,undefined
[3] Institut Jules Bordet,undefined
[4] Centres Hospitaliers Jolimont,undefined
[5] Hospital Universitario San Carlos,undefined
[6] Biomedical Research Institute INCLIVA,undefined
[7] University of Valencia,undefined
[8] Eli Lilly and Company,undefined
[9] Eli Lilly and Company,undefined
[10] Eli Lilly and Company,undefined
来源：
British Journal of Cancer | 2016年 / 114卷
关键词：
advanced colorectal cancer; modified FOLFOX6; necitumumab; KRAS; EGFR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：372 / 380
页数：8
相关论文
共 50 条
  • [21] FOLFOX6 AS FIRST LINE TREATMENT IN METASTATIC GASTRIC CANCER: PRELIMINARY RESULTS OF A PHASE II TRIAL
    Fontana, A.
    Losi, L.
    Bertolini, F.
    Zironi, S.
    Depenni, R.
    Malavasi, N.
    Scarabelli, L.
    Luppi, G.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2009, 20
  • [22] A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer
    Wang, Xiang
    Zhao, Lin
    Liu, Hongfeng
    Zhong, Dingrong
    Liu, Wei
    Shan, Guangliang
    Dong, Fen
    Gao, Weisheng
    Bai, Chunmei
    Li, Xiaoyi
    BRITISH JOURNAL OF CANCER, 2016, 114 (12) : 1326 - 1333
  • [23] High-versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer
    Reynolds, Jana
    Chamberland-Tremblay, April
    Herrington, Jon D.
    Maldonado, Yolanda Munoz
    Wong, Lucas
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (03) : 173 - 178
  • [24] A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer
    Zhao, Jian Guo
    Qiu, Feng
    Xiong, Jian Ping
    Zhang, Ling
    Xiang, Xiao Jun
    Yu, Feng
    Yan, Jun
    Zhan, Zhen Yu
    Feng, Miao
    ANTI-CANCER DRUGS, 2009, 20 (04) : 281 - 286
  • [25] Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab
    Otsu, Satoshi
    Hirashima, Yoshinori
    Nishikawa, Kazuo
    Sakashita, Hiroyuki
    Morinaga, Ryotaro
    Watanabe, Koichiro
    Shirao, Kuniaki
    JAPANESE CLINICAL MEDICINE, 2014, 5 : 19 - 23
  • [26] Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
    Bendell, Johanna C.
    Tournigand, Christophe
    Swieboda-Sadlej, Anna
    Barone, Carlo
    Wainberg, Zev A.
    Kim, Jong Gwang
    Pericay, Carles
    Pastorelli, Davide
    Tarazi, Jamal
    Rosbrook, Brad
    Bloom, Joanna
    Ricart, Alejandro D.
    Kim, Sinil
    Sobrero, Alberto F.
    CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 239 - 247
  • [27] Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer:: a phase II study
    Feliu, J
    Salud, A
    Escudero, P
    Lòpez-Gómez, L
    Pericay, C
    Castañón, C
    de Tejada, MRL
    Rodríguez-García, JM
    Martínez, MP
    Martín, MS
    Sánchez, JJ
    Barón, MG
    BRITISH JOURNAL OF CANCER, 2004, 90 (08) : 1502 - 1507
  • [28] Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
    J Feliu
    A Salud
    P Escudero
    L López-Gómez
    C Pericay
    C Castañón
    M R López de Tejada
    J M Rodríguez-García
    M P Martínez
    M Sanz Martín
    J J Sánchez
    M González Barón
    British Journal of Cancer, 2004, 90 : 1502 - 1507
  • [29] Phase I Study of Sunitinib plus Modified FOLFOX6 in Japanese Patients with Treatment-naive Colorectal Cancer
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    Kato, Ken
    Yasui, Hirofumi
    Boku, Narikazu
    Lechuga, Maria Jose
    Hirohashi, Tomoko
    Shbata, Atsushi
    Hashigaki, Satoshi
    Li, Yinhua
    Ohtsu, Atsushi
    ANTICANCER RESEARCH, 2012, 32 (03) : 973 - 979
  • [30] A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
    Wainberg, Zev A.
    Messersmith, Wells A.
    Peddi, Parvin F.
    Kapp, Amy V.
    Ashkenazi, Avi
    Royer-Joo, Stephanie
    Portera, Chia C.
    Kozloff, Mark F.
    CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 248 - 254
12345